• Through screening 31 DNA-encoded chemical libraries, totaling 4.4 billion molecules, we identified a novel class of selective CDK2 inhibitors. • The drug-likeness of C172 at the cellular level was evaluated, such as in vitro enzymatic and cellular assays, mechanistic studies on protein degradation, ADME characterization, single-dose pharmacokinetics in rats and metabolite identification.